SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-016715
Filing Date
2024-01-26
Accepted
2024-01-26 16:08:54
Documents
17
Period of Report
2024-01-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d642740d8k.htm   iXBRL 8-K 39763
2 EX-4.1 d642740dex41.htm EX-4.1 88728
3 EX-10.1 d642740dex101.htm EX-10.1 275863
4 EX-10.2 d642740dex102.htm EX-10.2 131475
5 EX-99.1 d642740dex991.htm EX-99.1 12050
9 GRAPHIC g642740g0126132836129.jpg GRAPHIC 4303
  Complete submission text file 0001193125-24-016715.txt   803185

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA kura-20240124.xsd EX-101.SCH 2866
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE kura-20240124_lab.xml EX-101.LAB 17995
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kura-20240124_pre.xml EX-101.PRE 11272
11 EXTRACTED XBRL INSTANCE DOCUMENT d642740d8k_htm.xml XML 3353
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

IRS No.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 24567811
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)